The CJC-1295 (no DAC) + Ipamorelin blend is designed to model short-acting growth-hormone (GH) secretagogue activity. CJC-1295 (no DAC) is a tetrasubstituted peptide analog of growth-hormone-releasing hormone (GHRH), exhibiting a shorter half-life that supports controlled, pulse-based GH-release studies. Ipamorelin, a selective ghrelin receptor agonist, stimulates GH secretion through a complementary mechanism while avoiding significant elevations in cortisol or prolactin. When used together, these peptides allow researchers to investigate synergistic GH signaling and downstream IGF-1 expression under time-sensitive conditions. This combination provides a model for studying the neuroendocrine regulation of GH pulses, metabolic signaling cascades, and recovery-related protein synthesis. It is commonly used in experimental frameworks exploring muscle regeneration, energy metabolism, and pituitary response dynamics under varying dose-response and timing intervals. Regulatory Notice: This compound is intended solely for in-vitro laboratory and analytical research. It is not approved by the FDA for therapeutic, diagnostic, or clinical use in humans or animals. The Peptides Collective (TPC Research LLC) supplies this material exclusively to qualified professionals for lawful research purposes. Any use, sale, or reference suggesting human or veterinary application is strictly prohibited under these terms.